EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines

Robert L Joyner iD, Joseph A Hollenbaugh iD, Donald D'Aquila, Marc Fishman, Steven M Cohen iD, Veera Holdai, Jeffrey D Benner iD

Physiological Reports · 2024

DOI: 10.14814/phy2.16176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physiological Reports, 2024. Verfasst von Robert L Joyner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. Henson Research Institute, TidalHealth Peninsula Regional Salisbury, Salisbury, Maryland, USA. Hauptthemen laut MEDLINE: Fentanyl, Naltrexone, Respiratory Insufficiency, Absorbable Implants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study is to determine if extended‐release, bioabsorbable, subcutaneous naltrexone (NTX) implants can mitigate respiratory depression after an intravenous injection (IV) of fentanyl. Six different BIOabsorbable Polymeric Implant Naltrexone (BIOPIN) formulations, comprising combinations of Poly‐ d , l ‐Lactic Acid (PDLLA) and/or Polycaprolactone (PCL‐1 or PCL‐2), were used to create subcutaneous implants. Both placebo and naltrexone implants were implanted subcutaneously in male dogs. The active naltrexone implants consisted of two doses, 644 mg and 1288 mg. A challenge with IV fentanyl was performed in 33 male dogs at 97–100 days after implantation. Following the administration of a 30 μg/kg intravenous fentanyl dose, the placebo cohort manifested a swift and profound respiratory depression with a ~50% reduction in their pre‐dose respiratory rate (RR). The BIOPIN NTX‐implanted dogs were exposed to escalating doses of intravenous fentanyl (30 μg/kg, 60 μg/kg, 90 μg/kg, and 120 μg/kg). In contrast, the dogs implanted with the BIOPIN naltrexone implants tolerated doses up to 60 μg/kg without significant respiratory depression (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FentanylNaltrexoneRespiratory InsufficiencyAbsorbable ImplantsNarcotic AntagonistsDogsAnimalsMalePilot ProjectsAnalgesics, OpioidDelayed-Action Preparations

Stichwörter der Autor:innen

bioabsorbablecaninesfentanylimplantsnaltrexonerespiratory depression

Substanzen

FentanylNaltrexoneNarcotic AntagonistsAnalgesics, OpioidDelayed-Action Preparations

Autor:innen und Institutionen

  • Richard A. Henson Research Institute, TidalHealth Peninsula Regional Salisbury, Salisbury, Maryland, USA.
  • Labcorp, Greenfield, Indiana, USA.
  • The Department of Psychiatry Johns Hopkins School of Medicine and Maryland Treatment Centers, Baltimore, Maryland, USA.
  • The Drug Delivery Company, LLC Dba Akyso, Salisbury, Maryland, USA.
  • The Department of Mathematical Sciences, Salisbury University, Salisbury, Maryland, USA.

ORCID-Profile: Robert L Joyner, Joseph A Hollenbaugh, Steven M Cohen, Jeffrey D Benner

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse

Zitieren

APA

Joyner, R. L., Hollenbaugh, J. A., D'Aquila, D., Fishman, M., Cohen, S. M., Holdai, V., & Benner, J. D. (2024). Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines. Physiological Reports. https://doi.org/10.14814/phy2.16176

Vancouver

Joyner RL, Hollenbaugh JA, D'Aquila D, Fishman M, Cohen SM, Holdai V, et al. Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines. Physiological Reports. 2024. doi:10.14814/phy2.16176

BibTeX
@article{Joyner2024,
  author = {Joyner, Robert L and Hollenbaugh, Joseph A and D'Aquila, Donald and Fishman, Marc and Cohen, Steven M and Holdai, Veera and Benner, Jeffrey D},
  title = {Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines},
  journal = {Physiological Reports},
  year = {2024},
  doi = {10.14814/phy2.16176}
}
Kostenlos starten →